The Copper Ridge Institute (CRI) is evolving to become the Integrace Institute at Copper Ridge.
Integrace Institute at Copper Ridge is deeply committed to continuing research and education to support the care and treatment of individuals living with dementia. New initiatives, derived from an expanded emphasis on person-centered living and care practices, are also in development.
The goal of the Integrace Institute at Copper Ridge is to improve the quality of life for those with dementia, their loved ones, and the dedicated professionals who continue to devote their lives to this important work.
Please feel free to contact us with any questions or concerns.
Allison.firstname.lastname@example.org, Director of Dementia Education, (410) 795-8808 x 1116
Shannon.email@example.com, Research Coordinator, (410) 795-8808 x 1150
Below is a list of lectures for our Dementia Scholar Series. These events take place at either our Sykesville or Eason, Maryland location and can be attended in person or be viewed via webinar.
To learn more about upcoming educational offerings, please contact Allison Ciborowski, Director of Dementia Education, by email at Allison.firstname.lastname@example.org or phone at (410) 795-8808 x 1116.
Delirium, Dementia and Depression: How to Recognize each when they Coexist
September 10, 2015, 11 am – 12 pm
Families and Staff: Strategies for building positive relationships
October 15, 2015, 11 am – 12 pm
Nutrition and Weight Loss in Persons with Dementia
May 12, 2016, 11 am – 12 pm
Personalized Medicine: Its Role in Dementia and Long-Term Care
June 9, 2016, 11 am – 12 pm
1. Dementia: Is it different in veterans?
2. Activity Programming for Individuals With Frontotemporal Dementia
3. Alzheimer’s Disease Research Update
4. Personalized Medicine: Its Role in Dementia and Long Term Care
5. Meeting the Needs of the Family
ERK AD-Index as a Diagnostic Test for Alzheimer’s disease
A prospective study, conducted in collaboration with the Blanchette Rockefeller Neuroscience Institute, to develop a definitive diagnostic test for Alzheimer’s disease using cultured skin cells.
Function- and Behavior-Focused Care for Nursing Home Residents with Dementia
A clinical study testing a socioecological model and methods of modifying nursing staff activities to motivate and engage residents in behaviors that increase function and physical activity while minimizing resistance to care and other behavioral symptoms.
Implementation and Evaluation of a Pain Assessment Tool in a Dementia Care Facility
Evaluation of a pain assessment tool of quality improvement; specifically, pain monitoring and management, accreditation compliance, and decreasing need for psychotropic medications.
The Lived Experience and Meaning of the ‘Source’ of Caring in the Lives of Caregivers
An interpretive, phenomenological study designed to assess the psychosocial changes experienced by female caregivers and to reveal the nature of the source and experience of their caring.
The Effects of Personally Meaningful Music on Mood and Behavior in Persons with Alzheimer’s disease: An Exploratory Pilot Study
An exploratory study to determine if personally-meaningful music is more effective in improving mood and behavior than similar music without personal meaning among individuals with advanced dementia due to Alzheimer’s disease.
Pharmacogenomics in Elderly Patients: A Randomized-Controlled Trial (RCT) to Evaluate the Clinical Utility of GeneSight Psychotropic in Long-Term Care Patients with Dementia
GeneSight® is a Medicare-reimbursable procedure that uses a combinatorial psychiatric pharmacogenomics (CPGx) multi-gene approach to produce a personalized interpretive report that categorizes psychotropic medications into one of three groups based on objective, evidence-based, gene-drug interactions. This study will evaluate the clinical utility of GeneSight® for guiding psychotropic medication prescribing behavior of long-term care physicians, and on patient outcomes.
Phase III Trial of NUEDEXTA® for the Treatment of Agitation in Patients with Alzheimer’s disease
A clinical study to further assess the benefits and safety of NUEDEXTA® for treating agitation in Alzheimer’s disease. NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) is an oral investigational drug which has shown some possible benefits in treating behavioral symptoms in previous studies with other medical conditions.
To learn more about our current and prospective research initiatives, please contact Shannon O’Connor, MA, PhD(c), MS(c), Research Coordinator by email at Shannon.email@example.com or phone at (410) 795-8808 x 1150.